Pfizer India

The surge came after the company announced its fourth quarter results of financial year 2024 (Q4FY24) results

Q4 FY24 company results: Delhivery, JSW Steel, Godrej Industries, Bandhan Bank and many more companies are slated to release their fourth-quarter earnings

Their investment pledges came as President Emmanuel Macron prepared to kick off on Monday the annual 'Choose France' event aimed at wooing big overseas businesses and investors

The Pfizer INDovation initiative, which has supported 34 startups in India till now, is now expanding its reach through this collaboration with NIPER Ahmedabad

India's first indigenously developed COVID-19 vaccine, Corbevax, has been granted an Emergency Use Listing by the World Health Organisation, the company which manufactures it in India said here on Tuesday. Corbevax is based on a protein sub-unit platform and manufactured by the pharmaceutical firm Biological E Limited in India. Mahima Datla, Managing Director of Biological E Ltd said: We are pleased with the WHO Emergency Use Listing (EUL) because it would help us use the platform to continue developing COVID-19 vaccines as and when it starts impacting public health. We are confident that this endorsement from WHO will bolster our global fight against COVID-19.'' The Drugs Controller General of India (DCGI) had already approved Corbevax for restricted use in emergency among adults, adolescents and young children in a sequential manner from December 2021 to April 2022. It was also given approval for use as India's first heterologous COVID-19 booster shot for adults aged 18 and above

Stocks to watch on October 30, 2023: Fincare Small Finance Bank is set to merge with AU Small Finance Bank (AU SFB) in an all-share deal; Gujarat Gas has hiked industrial gas price to Rs 45.6 per scm

Drug firm Pfizer Ltd on Saturday reported 52.11 per cent decline in net profit at Rs 148.96 crore for the second quarter ended September 2023. The company had logged a net profit of Rs 311.07 crore in July-September period a year ago, according to a regulatory filing by Pfizer. Revenue from operations declined 9.76 per cent to Rs 575.21 crore in the quarter as against Rs 637.47 crore in the year-ago period. Total expense was at Rs 410.76 crore, down 5.66 per cent. Total income was at Rs 611.28 crore in September quarter 2023-24, down 7.62 per cent.

Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are in less than expected and cut revenue expectations for the year by USD 9 billion. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slid nearly 3 per cent before the opening bell Monday and Moderna, which makes a competing vaccine, slid as well. The company said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations. The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year. Full-year revenue for Paxlovid and Comirnaty is expected to be approximately USD 12.5 billion, short USD 9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by .

Investigating matter with contract manufacturer Astral Steritech, says pharma firm

Stockists have been asked not to sell, distribute, or use the products until further notice from Pfizer

Its cost of materials consumed fell 2.1% to Rs 94.4 crore, accounting for about 21% of total expenses in the quarter

"There's no editors anymore," Biden added. "There's no editors. How do we expect kids to be able to understand what is at stake?"

Over the past 14 years, Sridhar has led a number of key leadership positions in Pfizer, including serving as the Chief Financial Officer for a period of eight years

The centre integrates two essential functions under the export-oriented undertaking of Pfizer: Pharmaceutical Sciences (PharmSci) and Global Technology and Engineering (GT&E) Centre of Excellence.

Pfizer is near its long-term support, which it has defended for the last five years. A rebound can trigger a 10 per cent upside for the stock.

Announcing the appointment, S Sridhar, the managing director of the company, said with Pradip Shah's elevation as the chairman, the firm will work closely with him on matters of strategic importance

The broader markets logged smart gains for the third straight trading session; Advancing shares outnumbered declining stocks in nearly 2:1 ratio on the BSE

Pfizer beat third-quarter expectations and raised its 2021 forecast again even as sales of its top product, the COVID-19 vaccine Comirnaty, slipped in the U.S.

Sources close to the developments had indicated earlier that the price for India could be below $10 per dose, or the lowest in the world

"We have also helped expedite the introduction of Sputnik-V vaccines," the external affairs ministry spokesperson Arindam Bagchi told ANI.